CARB-X Brings the San Diego AMR Community Together
On Tuesday July 18, CARB-X, one of the world’s largest public private partnerships focused on combating antimicrobial resistance (AMR), held a standing-room only event at BioLabs in San Diego. The purpose of the event was to: (1) bring together the antimicrobial resistance community in the greater San Diego area; (2) provide information about the mission and model of CARB-X; and (3) feature Forge Therapeutics and Cidara Therapeutics, the two San Diego companies that won CARB-X awards of up to $15M together in the first round of funding.
Ninety-four people were in attendance, including experienced life science executives, life science startups and pre-formation companies, as well as well-known academic leaders in the field from UCSD, Scripps and the California Institute for Biomedical Research. Companies and researchers represented a wide range of AMR fields, such as phage therapy, diagnostics, traditional small molecules and biologics, and were joined by partners in several industry-academic collaborations.
Heather Shane, Executive Director of CLSI’s west coast CARB-X accelerator, opened the program with an overview of CARB-X and qualifications for accessing its non-dilutive funding. Ms. Shane then moderated a panel featuring Neil Abdollahian, Chief Business Officer of Cidara Therapeutics, and Zachary Zimmerman, CEO of Forge Therapeutics, followed by an active exchange and networking reception with attendees. “This was a great event! Very lively discussions with people interested in the AMR space,” posted Karen Joy Shaw, Chief Scientific Officer at Amyplyx Pharmaceuticals, and leader in the AMR community.
Click here to read some of the attendee responses.